Last reviewed · How we verify
NCT04780022: PFO-Elderly
Patent Foramen Ovale Closure in Older Patients
trial testing Clinical events at last follow-up in Patent Foramen Ovale in 350 participants. Completed in 1 December 2021.
1 December 2021
Quick facts
| Lead sponsor | Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 350 |
| Start date | 1 April 2021 |
| Primary completion | 1 December 2021 |
| Estimated completion | 1 December 2021 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Clinical events at last follow-up
Conditions studied
- Patent Foramen Ovale — all drugs for Patent Foramen Ovale →
- Ischemic Stroke — all drugs for Ischemic Stroke →
- Older People — all drugs for Older People →
Sponsor
Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec — full company profile →
Who can join
60 and older, any sex, with Patent Foramen Ovale or Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
* Describe the baseline and procedural characteristics of older patients undergoing PFO closure due to cryptogenic embolism. * Assess the long-term follow-up of this cohort, focusing on neurological events and their origin, major cardiac outcomes, as well as survival rates and death origin. * Seek for predictors of neurological event recurrence after the procedure.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04780022
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Patent Foramen Ovale
Currently open trials in the same condition.
- NCT07170176 — Effects of PFO Closure on Glymphatic Function and Clinical Symptoms in Patients With Migraine · NA · recruiting
- NCT05907694 — Medical Treatment With or Without Transcatheter Patent Foramen Ovale Closure · NA · recruiting
- NCT06953622 — Establishment of a Clinical and Prognostic Follow-up Cohort of Migraine Patients With Patent Foramen Ovale · recruiting
- NCT06156670 — Russian Registry of Endovascular Closure of PFO · recruiting
- NCT05387954 — PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years · Phase 3 · recruiting
Other Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec trials
Trials by the same sponsor.
- NCT04719845 — DilAtation Versus Endoscopic Laser Resection in Simple Benign trAcheal sTEnosis · NA · unknown
- NCT04405102 — COVID-19 Ozanimod Intervention Study · Phase 2 · terminated
- NCT04415242 — IMPACT OF OPERATIVE POSITIONING ON THE DEVELOPMENT OF SHOULDER PAIN AFTER PULMONARY LOBECTOMY BY VATS · NA · unknown
- NCT04139616 — Prospective Validation of a Pre-Specified Algorithm for the Management of Conduction Disturbances Following TAVR · recruiting
- NCT03683355 — Characterization of RadiOlabeled Tracer Uptake Pattern in Noninfected Transcatheter Aortic Valves. · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04780022 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
- Last refreshed: 2 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04780022.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing